2月10日，白云山（600332/00874）发布公告，公司分公司何济公制药厂收到国家药监局签发的《药品补充申请批准通知书》。
此次公告主要涉及药品口洁喷雾剂的规格变更，具体为将规格由“每瓶装20ml”变更为“每1ml相当于饮片240mg、含薄荷脑13mg、桉油2.5μl”。该申请于2025年11月4日递交，并于2025年11月17日获得受理。
截至公告日，何济公制药厂在口洁喷雾剂研发项目上已投入研发费用合计约241万元（未审计）。根据米内网数据显示，2024年口洁喷雾剂在国内市场的销售额为5064万元，而该药品的销售收入为1894万元。
此次获得的批准通知书将规范药品规格表述，保障临床用药的剂量精准和用药安全有效，对公司当期业绩无重大影响。
2025年前三季度，白云山实现收入616.06亿元，归母净利润33.10亿元。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.